USA and Japanese scientists to share Nobel prize for cancer work

Leslie Hanson
October 3, 2018

DD NewsTwo immunologists, James Allison of the United States and Tasuku Honjo of Japan won the 2018 Nobel prize in medicine for discovery of a revolutionary approach to cancer treatment.

Of the two treatment strategies, checkpoint therapy against PD-1 has proven more effective and positive results are being observed in several types of cancer, including lung cancer, renal cancer, lymphoma, and melanoma. I saw my children grow up and get married. That role partly falls to a white blood cell known as a "T cell". Allison then developed a "checkpoint inhibitor", or a drug that releases that brake, and enables the patient's immune system to identify and confront tumors.

The discovery made by the two laureates "constitutes a landmark in our fight against cancer", the committee tweeted shortly after the announcement. An Ono Pharmaceutical representative commented, "It is a drug that can suppress cancer's progress, possibly allowing patients with the disease to lead an ordinary life".

The physics prize is to be announced Tuesday, followed by chemistry.

Later in the news conference he added, "Science is a long and frustrating road".

Allison went into cancer research because he always wanted to be the first person to figure something out.

"I never dreamed my research would take the direction it has", Allison said. He said that clinicians and investigators have come to accept immunotherapy as the fourth pillar of cancer care along with radiation, surgery, and chemotherapy.

While Allison is touted as an immunotherapy trailblazer, Opdivo is said to have fewer side effects than Yervoy.

"I had lung cancer", the member was quoted as saying, "and thought I was playing my last round of golf".

James P. Allison, 70, was born in Alice, Texas. As a researcher, "I like being on the edge and being wrong a lot". It was a breakthrough drug that turned an invariably fatal cancer that killed patients within months into one that could be cured, albeit in only a minority (about 20 percent) of patients.


That ability to work against different types of cancer is unusual and shows great promise, said Karre.

The binding of the antibodies to their respective T cell brake is the molecular equivalent of letting the foot off the brake pedal - it releases the inhibition on T cells so they can target tumour cells.

Before joining MD Anderson, Allison received both his bachelor's and doctorate degrees from UT Austin. He holds the Vivian Smith Distinguished Chair in Immunology and serves as deputy director of the David H. Koch Center for Applied Research in Genitourinary Cancers in the Department of Genitourinary Medical Oncology.

Professor Allison works at the MD Anderson Cancer Center, Houston.

He has collaboratively worked with scientists around the globe to expand the field of immunotherapy. A 2017 profile in The Washington Post dubbed them a "cancer-fighting power couple" and noted that "Allison has battled early-stage melanoma, bladder and prostate cancers".

The prize for physiology or medicine is first Nobel Prize awarded each year.

"It was a desperate time for the treatment of melanoma", Ribas said.

Allison said he has been professionally friendly with Honjo since the 1980s. This is the second year in a row that a Longhorn has won the coveted award.

Dr. Jedd Wolchok is chief of the melanoma and immunotherapeutics service at the Memorial Sloan Kettering Cancer Center in NY.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER